Vox Ventures’ Post

Despite slower deal markets in 2023, transacted deal value actually rose in pharma and medtech. Life science strategics still have plenty of cash reserves and a recent Bain survey shows more activity is likely to come. Read more from Bain's annual M&A report.

“…2024 could be more about survival than growth for many organizations.” At the start of the year, our marketing wizard, Alec de la Durantaye 🧙♂️ , wrote an excellent blog wrapping up the 2023 funding calendar year.  💰 Breaking down funding trends by geography, company size, therapeutic area, and more, the article provides some valuable insights for the Biopharma service industry… ➡ Which states are beefing up their healthcare game in what is the fast-growing sector? (way to go Tennessee!) ➡ Which therapeutic areas are grabbing the funding spotlight? (Ophthalmology, the dark horse coming in at 4th place 👁 ) ➡ What does funding around the globe look like? 🌎 (Average amount received by companies lowest for NA…) Turns out…the future looks bright - and if you’re a CRO or CDMO (or other type of service provider) - opportunities abound! 🌟 As investors look to de-risk, the majority of investment is being funneled into a larger number of small to mid-sized companies (500 employees or less), all of which, in turn, will be seeking partners to help them progress their assets. 🤝 - 📆 Next week, The SCOPE Summit 2024 will provide an opportunity for industry-wide collaboration, innovation, and strategic decision-making in the field of clinical trials and research. 🔬 84 of the companies attending SCOPE fall into the above-mentioned well-funded 500 employees or less category and will be looking for support! 💪 The key for service providers will be targeting the companies with the right projects at the right stage. 🎯 If you’d like to get some visibility into the attending companies and who to prioritize connecting with (based on your services)… ...or you’d like to see how Zymewire can help you target these companies beyond the #SCOPE2024 conference… shoot me a DM! #SCOPE2024 #biopharmafunding #clinicalresearch

The clinical drug development market has experienced significant advancements in recent years. At the same time, this surge of innovation has created unprecedented complexity for life sciences organizations.   For companies that want to harness the power of breakthrough innovations, they must first break through the challenges. Our new video and POV explains how Capgemini is helping organizations create a next-gen clinical development capability to increase program efficiency, speed, and access.   Click here to know more: https://bit.ly/3u3vPzW #LifeSciences #ClinicalDevelopment #Innovation #nextgenclinicaldevelopment 

🔍 Is Pharma Ready for the Digital Health Revolution? 🔍 🤍🤍🤍 Digital health is rapidly evolving, transforming patient care, and challenging traditional pharmaceutical sales and marketing strategies. ☝️ But are we, the pharma industry, truly ready to embrace this revolution? 🔶 The digital health market is projected to exceed $500 billion by 2025, driven by advancements in telehealth, AI diagnostics, and drug delivery systems. This growth demands a shift in how pharma companies approach sales and marketing. 🌟 Adapting to this new landscape means: [1] Reevaluating our sales force's role. [2] Investing in digital literacy. [3] Exploring partnerships with tech companies. It's an exciting yet challenging time that necessitates a mindset shift from traditional methodologies to innovative approaches. As we navigate this digital transformation, we must stay ahead of the curve, understanding that the ultimate goal is improving patient outcomes. Let's engage in this journey together, reshaping our industry for a healthier tomorrow.

🚨 Who's ready for another Zapyrus MedTech in Numbers report?! 🚨 An additional $8.77 billion in funding in Q2 has pushed the total funding in 2024 well beyond the total funding for all of 2023. 🤯 For anyone attending #ADLM2024 in Chicago next week, here's a quick snippet to validate that you're investing in the right space. 👇 "This large spike in the growth of IVD and SaMD in an overall decrease in the market funding totals suggests that investments are being pulled from traditional medical devices and put into the growing IVD and SaMD segments." #MedTech #IVD #SaMD #Businessdevelopment #BD

Adoption of new technologies, including AI, in areas such as drug development, study design, and patient care will lead to M&A and strategic partnerships, driving transformation in 2024. Read more #PwCDeals #ValueCreation #PrivateHealth #HealthCare

Adoption of new technologies, including AI, in areas such as drug development, study design, and patient care will lead to M&A and strategic partnerships, driving transformation in 2024. Read more #PwCDeals #ValueCreation #PrivateHealth #HealthCare

Adoption of new technologies, including AI, in areas such as drug development, study design, and patient care will lead to M&A and strategic partnerships, driving transformation in 2024. Read more #PwCDeals #ValueCreation #PrivateHealth #HealthCare

Adoption of new technologies, including AI, in areas such as drug development, study design, and patient care will lead to M&A and strategic partnerships, driving transformation in 2024. Read more #PwCDeals #ValueCreation #PrivateHealth #HealthCare

Adoption of new technologies, including AI, in areas such as drug development, study design, and patient care will lead to M&A and strategic partnerships, driving transformation in 2024. Read more #PwCDeals #ValueCreation #PrivateHealth #HealthCare